These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 16128605)
1. Biologics in the treatment of transplant rejection and ischemia/reperfusion injury: new applications for TNFalpha inhibitors? Pascher A; Klupp J BioDrugs; 2005; 19(4):211-31. PubMed ID: 16128605 [TBL] [Abstract][Full Text] [Related]
2. Short-term TNF-alpha inhibition reduces short-term and long-term inflammatory changes post-ischemia/reperfusion in rat intestinal transplantation. Gerlach UA; Atanasov G; Wallenta L; Polenz D; Reutzel-Selke A; Kloepfel M; Jurisch A; Marksteiner M; Loddenkemper C; Neuhaus P; Sawitzki B; Pascher A Transplantation; 2014 Apr; 97(7):732-9. PubMed ID: 24598936 [TBL] [Abstract][Full Text] [Related]
3. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839 [TBL] [Abstract][Full Text] [Related]
4. Tacrolimus: a further update of its use in the management of organ transplantation. Scott LJ; McKeage K; Keam SJ; Plosker GL Drugs; 2003; 63(12):1247-97. PubMed ID: 12790696 [TBL] [Abstract][Full Text] [Related]
7. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group. Gruessner RW Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719 [TBL] [Abstract][Full Text] [Related]
8. Daclizumab: a review of its use in the management of organ transplantation. Carswell CI; Plosker GL; Wagstaff AJ BioDrugs; 2001; 15(11):745-73. PubMed ID: 11707149 [TBL] [Abstract][Full Text] [Related]
9. Antibodies against tumor necrosis factor prolong cardiac allograft survival in the rat. Lin H; Chensue SW; Strieter RM; Remick DG; Gallagher KP; Bolling SF; Kunkel SL J Heart Lung Transplant; 1992; 11(2 Pt 1):330-5. PubMed ID: 1576139 [TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status. Swiatecka-Urban A Paediatr Drugs; 2003; 5(10):699-716. PubMed ID: 14510627 [TBL] [Abstract][Full Text] [Related]
11. Muromonab CD3. A review of its pharmacology and therapeutic potential. Todd PA; Brogden RN Drugs; 1989 Jun; 37(6):871-99. PubMed ID: 2503348 [TBL] [Abstract][Full Text] [Related]
12. Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review. Toussirot E; Streit G; Wendling D Recent Pat Inflamm Allergy Drug Discov; 2007 Feb; 1(1):39-47. PubMed ID: 19075965 [TBL] [Abstract][Full Text] [Related]
13. Reduction of obliterative bronchiolitis (OB) by prolyl-hydroxylase-inhibitors activating hypoxia-inducible transcription factors in an experimental mouse model. Heim C; Motsch B; Jalilova S; Bernhardt WM; Ramsperger-Gleixner M; Burzlaff N; Weyand M; Eckardt KU; Ensminger SM Transpl Immunol; 2016 Nov; 39():66-73. PubMed ID: 27590486 [TBL] [Abstract][Full Text] [Related]